Cutaneous squamous cell carcinoma
Revision as of 18:24, 7 August 2018 by Jwarner (talk | contribs) (Jwarner moved page Squamous cell carcinoma (SCC) to Cutaneous squamous cell carcinoma)
| Section editor | |
|---|---|
 |
Elizabeth Buchbinder, MD Boston, MA |
6 regimens on this page
9 variants on this page
|
Neoadjuvant chemotherapy
Bleomycin & Cisplatin
| back to top |
Regimen
| Study | Evidence |
|---|---|
| Denic et al. 1999 | Pilot, <20 patients reported |
Neoadjuvant case reports only.
Chemotherapy
- Cisplatin (Platinol) 20 mg/m2 IV once per day on days 1 to 4
- Bleomycin (Blenoxane) 20 mg IV once per day on days 1 to 4
21-day cycle for 3 cycles
References
- Denic S. Preoperative treatment of advanced skin carcinoma with cisplatin and bleomycin. Am J Clin Oncol. 1999 Feb;22(1):32-4. link to original article contains protocol PubMed
Advanced or metastatic disease, all lines of therapy
Cetuximab monotherapy
| back to top |
Variant #1, weekly, indefinite
| Study | Evidence |
|---|---|
| Maubec et al. 2011 | Phase II |
Chemotherapy
- Cetuximab (Erbitux) 400 mg/m2 IV once, then 250 mg/m2 IV once per week
Given for at least 6 weeks, to be continued until progression of disease or unacceptable toxicity
Variant #2, weekly x 3 mo
| Study | Evidence |
|---|---|
| Kim et al. 2011 | Case report |
Chemotherapy
- Cetuximab (Erbitux) 400 mg/m2 IV once, then 250 mg/m2 IV once per week
3 month course
Variant #3, intermittent
| Study | Evidence |
|---|---|
| Miller et al. 2010 | Case report |
Chemotherapy
- Cetuximab (Erbitux) 400 mg/m2 IV once on day 1, then 250 mg/m2 IV once per day on days 8, 15, 22
6-month cycles, given indefinitely unless progression occurs
References
- Case report: Bauman JE, Eaton KD, Martins RG. Treatment of recurrent squamous cell carcinoma of the skin with cetuximab. Arch Dermatol. 2007 Jul;143(7):889-92. link to original article PubMed
- Case report: Suen JK, Bressler L, Shord SS, Warso M, Villano JL. Cutaneous squamous cell carcinoma responding serially to single-agent cetuximab. Anticancer Drugs. 2007 Aug;18(7):827-9. link to original article PubMed
- Case report: Arnold AW, Bruckner-Tuderman L, Zuger C, Itin PH. Cetuximab therapy of metastasizing cutaneous squamous cell carcinoma in a patient with severe recessive dystrophic epidermolysis bullosa. Dermatology. 2009;219(1):80-3. Epub 2009 May 13. link to original article PubMed
- Case report: Miller K, Sherman W, Ratner D. Complete clinical response to cetuximab in a patient with metastatic cutaneous squamous cell carcinoma. Dermatol Surg. 2010 Dec;36(12):2069-74. Epub 2010 Oct 11. link to original article contains verified protocol PubMed content property of HemOnc.org
- Case report: Kim S, Eleff M, Nicolaou N. Cetuximab as primary treatment for cutaneous squamous cell carcinoma to the neck. Head Neck. 2011 Feb;33(2):286-8. link to original article contains verified protocol PubMed
- Maubec E, Petrow P, Scheer-Senyarich I, Duvillard P, Lacroix L, Gelly J, Certain A, Duval X, Crickx B, Buffard V, Basset-Seguin N, Saez P, Duval-Modeste AB, Adamski H, Mansard S, Grange F, Dompmartin A, Faivre S, Mentré F, Avril MF. Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol. 2011 Sep 1;29(25):3419-26. Epub 2011 Aug 1. link to original article contains verified protocol PubMed
Cisplatin & Doxorubicin
| back to top |
Regimen
| Study | Evidence |
|---|---|
| Guthrie et al. 1990 | Non-randomized |
Chemotherapy
- Cisplatin (Platinol) 75 mg/m2 IV once on day 1
- Doxorubicin (Adriamycin) 50 mg/m2 IV once on day 1
21-day cycles
References
- Case series: Guthrie TH, Porubsky ES. Successful systemic chemotherapy of advanced squamous and basal cell carcinoma of the skin with cis-diamminedichloroplatinum III and doxorubicin. Laryngoscope. 1982 Nov;92(11):1298-9. link to original article PubMed
- Case series: Guthrie TH Jr, McElveen LJ, Porubsky ES, Harmon JD. Cisplatin and doxorubicin. An effective chemotherapy combination in the treatment of advanced basal cell and squamous carcinoma of the skin. Cancer. 1985 Apr 15;55(8):1629-32. PubMed
- Case series: Guthrie TH Jr, Porubsky ES, Luxenberg MN, Shah KJ, Wurtz KL, Watson PR. Cisplatin-based chemotherapy in advanced basal and squamous cell carcinomas of the skin: results in 28 patients including 13 patients receiving multimodality therapy. J Clin Oncol. 1990 Feb;8(2):342-6. link to original article contains verified protocol PubMed
Cisplatin, Interferon alfa-2a, Isotretinoin
| back to top |
Regimen
| Study | Evidence |
|---|---|
| Shin et al. 2002 | Phase II |
Note: Shin et al. 2002 did not clearly specify whether the interferon alfa used in the trial was 2a or 2b, but based on the details in the paper and the references cited, it is inferred that interferon alfa-2a was used.
Chemoimmunotherapy
- Interferon alfa-2a (Roferon-A) 5,000,000 units/m2 SC 3 times per week
- Isotretinoin (Accutane) 1 mg/kg PO once per day
- Cisplatin (Platinol) 20 mg/m2 IV once per week
References
- Shin DM, Glisson BS, Khuri FR, Clifford JL, Clayman G, Benner SE, Forastiere AA, Ginsberg L, Liu D, Lee JJ, Myers J, Goepfert H, Lotan R, Hong WK, Lippman SM. Phase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin cancer. J Clin Oncol. 2002 Jan 15;20(2):364-70. link to original article contains verified protocol PubMed
Investigational agents
Drugs with some degree of promising activity in clinical trials.